Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 3745 - 3752 of 12089 results
Paid Sick Leave Arrives for New York State Employers & New York City Amends Its Own Paid Sick Leave Law
September 30, 2020| Blog| Viewpoint
FERC Order Removes Barriers for Distributed Energy Resource Aggregations in Wholesale Markets
September 30, 2020| Blog| Viewpoint
Mintz Snags Former Kirkland & Ellis Partner In LA
September 30, 2020| News
In Latest Partner Hire, Mintz Adds M&A Lawyer from McDermott
September 30, 2020| News
Federal Court Halts USCIS Filing Fee Increases Nationwide
September 30, 2020| Alert| Viewpoint
Statutory – not Shareholder – Activism: Governor Newsom Signs California’s Diversity Mandate into Law
September 30, 2020| Blog| Viewpoint
COVID-19: Regulators Confronted with Scourge of ‘Fake Cures’
September 29, 2020| News
Final Canadian Drug Importation Rule and HHS Certification Issued Under Section 804 of the Food, Drug and Cosmetic Act
September 28, 2020| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|